IBDEI132 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,17412,0)
 ;;=R73.02^^88^891^95
 ;;^UTILITY(U,$J,358.3,17412,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17412,1,3,0)
 ;;=3^Impaired Glucose Tolerance (oral)
 ;;^UTILITY(U,$J,358.3,17412,1,4,0)
 ;;=4^R73.02
 ;;^UTILITY(U,$J,358.3,17412,2)
 ;;=^5019562
 ;;^UTILITY(U,$J,358.3,17413,0)
 ;;=R73.09^^88^891^18
 ;;^UTILITY(U,$J,358.3,17413,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17413,1,3,0)
 ;;=3^Abnormal Glucose NEC
 ;;^UTILITY(U,$J,358.3,17413,1,4,0)
 ;;=4^R73.09
 ;;^UTILITY(U,$J,358.3,17413,2)
 ;;=^5019563
 ;;^UTILITY(U,$J,358.3,17414,0)
 ;;=R73.9^^88^891^89
 ;;^UTILITY(U,$J,358.3,17414,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17414,1,3,0)
 ;;=3^Hyperglycemia,Unspec
 ;;^UTILITY(U,$J,358.3,17414,1,4,0)
 ;;=4^R73.9
 ;;^UTILITY(U,$J,358.3,17414,2)
 ;;=^5019564
 ;;^UTILITY(U,$J,358.3,17415,0)
 ;;=R76.11^^88^891^147
 ;;^UTILITY(U,$J,358.3,17415,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17415,1,3,0)
 ;;=3^Positive PPD
 ;;^UTILITY(U,$J,358.3,17415,1,4,0)
 ;;=4^R76.11
 ;;^UTILITY(U,$J,358.3,17415,2)
 ;;=^5019570
 ;;^UTILITY(U,$J,358.3,17416,0)
 ;;=R79.1^^88^891^3
 ;;^UTILITY(U,$J,358.3,17416,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17416,1,3,0)
 ;;=3^Abnormal Coagulation Profile
 ;;^UTILITY(U,$J,358.3,17416,1,4,0)
 ;;=4^R79.1
 ;;^UTILITY(U,$J,358.3,17416,2)
 ;;=^5019591
 ;;^UTILITY(U,$J,358.3,17417,0)
 ;;=R82.5^^88^891^74
 ;;^UTILITY(U,$J,358.3,17417,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17417,1,3,0)
 ;;=3^Elevated Urine Levels of Drug/Meds/Biol Subst
 ;;^UTILITY(U,$J,358.3,17417,1,4,0)
 ;;=4^R82.5
 ;;^UTILITY(U,$J,358.3,17417,2)
 ;;=^5019605
 ;;^UTILITY(U,$J,358.3,17418,0)
 ;;=R82.6^^88^891^30
 ;;^UTILITY(U,$J,358.3,17418,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17418,1,3,0)
 ;;=3^Abnormal Urine Levels of Subst of Nonmed Source
 ;;^UTILITY(U,$J,358.3,17418,1,4,0)
 ;;=4^R82.6
 ;;^UTILITY(U,$J,358.3,17418,2)
 ;;=^5019606
 ;;^UTILITY(U,$J,358.3,17419,0)
 ;;=R82.90^^88^891^29
 ;;^UTILITY(U,$J,358.3,17419,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17419,1,3,0)
 ;;=3^Abnormal Urine Findings,Unspec
 ;;^UTILITY(U,$J,358.3,17419,1,4,0)
 ;;=4^R82.90
 ;;^UTILITY(U,$J,358.3,17419,2)
 ;;=^5019609
 ;;^UTILITY(U,$J,358.3,17420,0)
 ;;=R82.91^^88^891^53
 ;;^UTILITY(U,$J,358.3,17420,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17420,1,3,0)
 ;;=3^Chromoabnormalities of Urine NEC
 ;;^UTILITY(U,$J,358.3,17420,1,4,0)
 ;;=4^R82.91
 ;;^UTILITY(U,$J,358.3,17420,2)
 ;;=^5019610
 ;;^UTILITY(U,$J,358.3,17421,0)
 ;;=R89.9^^88^891^22
 ;;^UTILITY(U,$J,358.3,17421,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17421,1,3,0)
 ;;=3^Abnormal Organ/Tissue Specimen Findings,Unspec
 ;;^UTILITY(U,$J,358.3,17421,1,4,0)
 ;;=4^R89.9
 ;;^UTILITY(U,$J,358.3,17421,2)
 ;;=^5019702
 ;;^UTILITY(U,$J,358.3,17422,0)
 ;;=R90.0^^88^891^103
 ;;^UTILITY(U,$J,358.3,17422,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17422,1,3,0)
 ;;=3^Intracranial Space-Occupying Lesion Dx Imaging of Central Nervous System
 ;;^UTILITY(U,$J,358.3,17422,1,4,0)
 ;;=4^R90.0
 ;;^UTILITY(U,$J,358.3,17422,2)
 ;;=^5019703
 ;;^UTILITY(U,$J,358.3,17423,0)
 ;;=R90.89^^88^891^16
 ;;^UTILITY(U,$J,358.3,17423,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,17423,1,3,0)
 ;;=3^Abnormal Findings on Dx Imaging of Central Nervous System NEC
 ;;^UTILITY(U,$J,358.3,17423,1,4,0)
 ;;=4^R90.89
 ;;^UTILITY(U,$J,358.3,17423,2)
 ;;=^5019706
 ;;^UTILITY(U,$J,358.3,17424,0)
 ;;=R91.8^^88^891^21
